Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 68,840	$ 61,761
Marketable securities	25,176	0
Trade receivables, net	8,303	0
Partnership receivables	1,205	1,197
Inventory	1,252	0
Clinical trial retainers	881	355
Other prepaid expenses and other current assets	2,320	2,195
Total current assets	107,977	65,508
Property and equipment, net	292	343
Operating lease right-of-use asset	560	903
Other assets	258	158
Total assets	109,087	66,912
Current liabilities:
Accounts payable	4,925	3,380
Accrued clinical trial costs and contract research	6,534	4,550
Other accrued liabilities	9,484	4,463
Operating lease liability	361	369
Loans payable, net of discount	0	1,056
Deferred revenue	1,072	1,974
Deferred research and development reimbursements	0	164
PIPE Warrant liability	0	199
Other liabilities (Note 6)	0	790
Total current liabilities	22,376	16,945
Loans payable, net of current portion and discount	33,026	12,716
Deferred revenue, non-current	0	578
Operating lease liability, non-current	19	336
Other liabilities, non-current (Note 6)	2,432	1,043
Total liabilities	57,853	31,618
Stockholders’ equity:
Preferred stock, $.001 par value: 5,000 shares authorized at September 30, 2021 and December 31, 2020; no shares issued and outstanding at each of September 30, 2021 and December 31, 2020	0	0
Common stock, $.001 par value: 50,000 shares authorized at September 30, 2021 and December 31, 2020; 34,374 shares issued and outstanding at September 30, 2021 and 26,883 issued and outstanding at December 31, 2020	34	27
Additional paid-in capital	718,494	656,472
Accumulated other comprehensive income	(2)	0
Accumulated deficit	(667,292)	(621,205)
Total stockholders’ equity	51,234	35,294
Total liabilities and stockholders’ equity	$ 109,087	$ 66,912